Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | SQLE | Q14534 | 8/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LSS | P48449 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123094 | 1.00 | KMT2A (0.77) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL138767 | 1.00 | KMT2A (0.77) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL2231674 | 1.00 | KMT2A (0.77) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL138766 | 1.00 | KMT2A (0.77) | KMT2ASQLEALOX15MAPTMEN1 | |
| Squalene SCHEMBL28323195 | 0.88 | KMT2A (0.81) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL8669621 | 0.88 | LSS (0.58) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL8669624 | 0.88 | LSS (0.58) | KMT2ASQLEALOX15MAPTMEN1 | |
| Squalene SCHEMBL8819997 | 0.88 | KMT2A (1.00) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL21639794 | 0.88 | KMT2A (1.00) | KMT2ASQLEALOX15MAPTMEN1 | |
| Squalene SCHEMBL21823197 | 0.88 | KMT2A (1.00) | KMT2ASQLEALOX15MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353805-A1 | PROCESS | GIVAUDAN SA (CH) | 2025-11-20 | — | — | US | disclosed |
| EP-4452914-A1 | PROCESS | Givaudan SA (CH) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118051-A1 | PROCESS | GIVAUDAN SA (CH) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353805-A1 | PROCESS | DEGS1, FDFT1, SQLE | KMT2A 3167/4885SQLE 3/4885ALOX15 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.